Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset
- PMID: 12707066
- DOI: 10.1001/archneur.60.4.529
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset
Abstract
Background: To our knowledge, no prior study has focused on subjects with Parkinson disease (PD) with elderly disease onset, and there is little evidence-based knowledge of treatment outcomes in these patients.
Objective: To compare the clinical presentation, comorbidities, treatment, and evolution of PD in patients with old-age onset with those of patients with middle-age onset in one US university center.
Design: In the Rush Movement Disorder Database, we retrieved 43 patients with PD with onset at 78 years or older. By using a case-control design, we assigned each patient with old-age PD onset 1 (n = 5) or 2 (n = 38) patients with middle-age PD onset, matched for disease duration but with disease onset between the ages of 43 and 66 years. We compared the groups on several clinical measures using conditional logistic regression.
Results: At a comparable length of PD duration (mean, 5.1 years for patients with old-age PD onset and 5.5 years for patients with middle-age PD onset), the total Unified Parkinson's Disease Rating Scale motor score was significantly higher in those with old-age PD onset than in those with middle-age PD onset (33.3 vs 21.2; P<.001). The patients with old-age onset had higher scores for rigidity (5.2 vs 4.3; P =.03), bradykinesia (13.0 vs 9.6; P =.001), and axial impairment (12.8 vs 5.2; P<.001), but not for tremor (2.2 vs 2.0; P =.68). They were more likely to have at least one comorbid condition compared with patients with middle-age onset (24 [56%] of 43 patients vs 20 [25%] of 81 patients; P =.002), but even when adjusting for comorbidities, they still maintained higher motor scores than controls. When treating patients with old-age PD onset, clinicians used levodopa monotherapy more frequently than in patients with middle-age PD onset (34 patients [79%] vs 16 patients [20%]; P<.001), and agonists were prescribed less frequently (5 patients [12%] vs 29 patients [36%]; P =.005).
Conclusions: At the same disease duration, patients with old-age PD onset have greater motor impairment than patients with middle-age PD onset. This difference may be due to more rapid disease progression, less aggressive or less potent medical treatment, the elderly age of the subjects with old-age PD onset at study end independent of disease onset, or yet-to-be elucidated influences of comorbid conditions. Focused research on old-age PD onset is important to delineate the confounding influences of aging and comorbidities and to establish the safety and efficacy of new treatments for this group of patients.
Comment in
-
Parkinson disease with old-age onset.Arch Neurol. 2003 Dec;60(12):1814-5. doi: 10.1001/archneur.60.12.1814. Arch Neurol. 2003. PMID: 14676066 No abstract available.
Similar articles
-
New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset.J Psychopharmacol. 2007 Jul;21(5):501-6. doi: 10.1177/0269881106073109. Epub 2007 Apr 19. J Psychopharmacol. 2007. PMID: 17446202
-
Contribution of aging to the severity of different motor signs in Parkinson disease.Arch Neurol. 2005 Mar;62(3):467-72. doi: 10.1001/archneur.62.3.467. Arch Neurol. 2005. PMID: 15767513
-
Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.Clin Neurol Neurosurg. 2005 Jun;107(4):306-9. doi: 10.1016/j.clineuro.2004.09.021. Epub 2004 Nov 11. Clin Neurol Neurosurg. 2005. PMID: 15885389
-
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021. Clin Ther. 2007. PMID: 18035186 Review.
-
Parkinson's disease. Update in diagnosis and symptom management.Geriatrics. 2001 Aug;56(8):24-5, 29-30, 33-5. Geriatrics. 2001. PMID: 11505857 Review.
Cited by
-
Trends in inpatient antiparkinson drug use in the USA, 2001-2012.Eur J Clin Pharmacol. 2015 Aug;71(8):1011-9. doi: 10.1007/s00228-015-1881-4. Epub 2015 Jun 18. Eur J Clin Pharmacol. 2015. PMID: 26081062 Free PMC article.
-
A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects.Inflammopharmacology. 2023 Apr;31(2):673-688. doi: 10.1007/s10787-023-01192-2. Epub 2023 Mar 24. Inflammopharmacology. 2023. PMID: 36961665 Review.
-
Quantitative measurement of trunk rigidity in parkinsonian patients.J Neurol. 2007 Feb;254(2):202-9. doi: 10.1007/s00415-006-0327-4. Epub 2007 Mar 2. J Neurol. 2007. PMID: 17334954
-
Age at onset as stratifier in idiopathic Parkinson's disease - effect of ageing and polygenic risk score on clinical phenotypes.NPJ Parkinsons Dis. 2022 Aug 9;8(1):102. doi: 10.1038/s41531-022-00342-7. NPJ Parkinsons Dis. 2022. PMID: 35945230 Free PMC article.
-
Comparison of auditory cueing in toe tapping and gait in persons with Parkinson's disease.Front Hum Neurosci. 2023 Sep 1;17:1197247. doi: 10.3389/fnhum.2023.1197247. eCollection 2023. Front Hum Neurosci. 2023. PMID: 37727863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical